Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.5K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.5K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.0K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

274
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
274
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.2K
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

93
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
93
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

142
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Responsible Research Practices in Pediatrics: How Reporting Guidelines Can Be Used to Improve Trial Design and Conduct.

The Journal of pediatrics·2026
Same author

Previable Preterm Premature Rupture of the Membranes Reaching Viability: Canadian Outcomes.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same authorSame journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocols.

The Lancet. Child & adolescent health·2026
Same author

CONSORT-Children and Adolescents (CONSORT-C) 2026 extension statement: enhancing the reporting and impact of paediatric randomised trials.

The Lancet. Child & adolescent health·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
See all related articles

Related Experiment Video

Updated: Nov 29, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.2K

A Bayesian response-adaptive dose-finding and comparative effectiveness trial.

Anna Heath1,2,3, Maryna Yaskina4, Petros Pechlivanoglou1,5

  • 1Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.

Clinical Trials (London, England)
|November 24, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces a novel trial design for evaluating new combination therapies, like intranasal ketamine and dexmedetomidine, in children. The adaptive design efficiently identifies optimal doses and compares effectiveness, speeding up access to safe treatments.

Keywords:
Bayesian analysisResponse-adaptive trialclinical trial designnon-inferiority trial

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.9K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.8K

Related Experiment Videos

Last Updated: Nov 29, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.2K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.9K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.8K

Area of Science:

  • Clinical Trials
  • Pharmacology
  • Pediatric Anesthesiology

Background:

  • Combination therapies offer benefits over individual treatments but face trial funding and prioritization challenges.
  • Novel trial designs are needed to efficiently evaluate combination therapies, especially those using approved drugs.
  • This study focuses on evaluating intranasal ketamine and dexmedetomidine combinations for pediatric fracture reduction.

Purpose of the Study:

  • To develop and validate a novel, adaptive trial design for evaluating combination therapies.
  • To facilitate the assessment of multiple dose combinations of ketamine and dexmedetomidine.
  • To compare the effectiveness of the optimal combination against a standard treatment in pediatric patients.

Main Methods:

  • Utilizing response-adaptive randomization to allocate patients to different dose combinations.
  • Employing Bayesian dose-response modeling for comparative effectiveness analysis.
  • Conducting simulation studies to determine adaptive thresholds and evaluate design operating characteristics.

Main Results:

  • The adaptive design demonstrated an 83% chance of allocating the most patients to the most effective dose combination.
  • Simulations showed a type I error <5% and 93% power for non-inferiority conclusion when the optimal combination is highly effective.
  • The trial design achieved >77% probability of meeting dual objectives (dose-finding and comparative effectiveness) with >90% Bayesian predictive power.

Conclusions:

  • The novel trial design efficiently determines optimal drug doses and assesses comparative effectiveness simultaneously.
  • This approach minimizes administrative burden and recruitment time, accelerating patient access to effective combination therapies.
  • The proposed design offers a feasible and powerful strategy for evaluating new combination therapies within a manageable sample size.